Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
NCT06575192 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of ARTIA in adult participants undergoing immediate, two-stage, implant-based breast reconstruction post-mastectomy.
Conditions Studied
Interventions
- OTHER No Intervention
- DEVICE ARTIA Reconstructive Tissue Matrix
Study Locations (20)
California
- Cedars-Sinai Medical Center /ID# 268326 — Los Angeles
- UC Irvine Medical Center /ID# 267428 — Orange
- Stanford University Medical Center CTRU - 800 Welch Road /ID# 264196 — Palo Alto
- South Bay Plastic Surgeons /ID# 264192 — Torrance
Illinois
- Rush University Medical Center /ID# 275935 — Chicago
- Endeavor Health /ID# 266302 — Northbrook
New York
- Northwell Health Clinical Trials Office /ID# 268076 — Lake Success
- NYU Langone Medical Center /ID# 265621 — New York
Tennessee
- Erlanger Health System /ID# 266608 — Chattanooga
- East Tennessee State University /ID# 264321 — Johnson City
Colorado
- University Of Colorado - Anschutz Medical Campus /ID# 268627 — Aurora
Florida
- University of Florida College of Medicine /ID# 267485 — Gainesville
Maryland
- Johns Hopkins Hospital /ID# 265917 — Baltimore
Missouri
- Washington University School of Medicine - St. Louis /ID# 264029 — St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 783 participants |
| Start Date | 2024-11-05 |
| Est. Completion | 2029-12 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06575192
The ClinicalTrials.gov registry entry for NCT06575192 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 783 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 603 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Breast Reconstruction appearing as the primary indexed condition, and to 2 interventions — of which No Intervention is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06575192 reports 20 study locations spanning 14 distinct geographic areas — top geographies include California, Illinois, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06575192 about?
NCT06575192 is a clinical study titled "Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants". The purpose of this study is to evaluate the safety and effectiveness of ARTIA in adult participants undergoing immediate, two-stage, implant-based breast reconstruction post-mastectomy.
What is the current status of trial NCT06575192?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 783 participants. The study started on 2024-11-05. Estimated completion is 2029-12.
What conditions does trial NCT06575192 study?
This clinical trial studies the following conditions: Breast Reconstruction. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06575192?
The interventions under investigation include: No Intervention (OTHER), ARTIA Reconstructive Tissue Matrix (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06575192?
This trial is sponsored by AbbVie, which has 603 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06575192 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.